Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms

Summary

Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.

Timeline

Start

2024-03-25

Primary completion

2024-12-03

Completion

2024-12-11

Publications

• Adler LA, Lieberman VR, Brijbasi L, Mattingly GW, Yarullina I, Li Y, Earnest J, Rubin J. Viloxazine Extended Release in Adults With Attention-Deficit/Hyperactivity Disorder and Depression and/or Anxiety Symptoms: Results From a Decentralized, Open-Label, Phase 4 Trial. J Clin Psychiatry. 2026 May 27;87(2):25m16234. doi: 10.4088/JCP.25m16234.

Drugs

Indications